C12N 2760/10041
Use of virus, viral particle or viral elements as a vector
C12N2760/10041 (Use of virus, viral particle or viral elements as a vector) appears on 25 US grants and 51 published applications in this corpus.
Search patents in C12N- Granted patents
- 25
- Published applications
- 51
- Assignees
- 13
- Inventors
- 82
- Latest grant
- 22 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 1 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 1 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 1 | 2 |
| 2017 | 1 | 3 |
| 2018 | 3 | 3 |
| 2019 | 0 | 4 |
| 2020 | 5 | 3 |
| 2021 | 1 | 6 |
| 2022 | 4 | 6 |
| 2023 | 4 | 4 |
| 2024 | 3 | 6 |
| 2025 | 2 | 8 |
| 2026 | 0 | 3 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/10043Viral genome or elements thereof as genetic vectorIndexing code21
- C12N 2760/10044Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code2
- C12N 2760/10045Special targeting system for viral vectorsIndexing code2
- C12N 2760/10042Virus or viral particle as vehicleIndexing code0
Recent patents
- HBV vaccines and methods treating HBV22 Jul 2025US 12,364,751 B2Gilead Sciences, Inc.
- Replication-defective arenavirus vectors18 Feb 2025US 12,227,755 B2UniversitäT ZüRich
- HIV vaccines and methods of using6 Aug 2024US 12,053,517 B2Gilead Sciences, Inc.
- Pichinde virus reverse genetics systems and methods of use28 May 2024US 11,993,789 B2Regents of the University of Minnesota
- Lassa vaccine7 May 2024US 11,976,305 B2Centre National De La Recherche Scientifique
- Multivalent vaccines against tuberculosis30 Jul 2026US 2026/0218232 A1Regents of the University of Minnesota
- Tri-segmented pichinde viruses as vaccine vectors23 Apr 2026US 2026/0109736 A1Hookipa Biotech GmbH
- Hbv vaccines and methods treating hbv26 Feb 2026US 2026/0053910 A1Gilead Sciences, Inc.
- Replication-defective arenavirus vectors4 Dec 2025US 2025/0369015 A1UniversitäT ZüRich
- Multivalent mopevac-based immunogenic composition for vaccination against new world arenaviruses and therapeutic use(s) thereof3 Jul 2025US 2025/0213670 A1
Most cited
By later US patents
- Replication-defective arenavirus vectors17US 8,592,205 B2UniversitäT ZüRich · 2013
- Replication-defective arenavirus vectors13US 9,309,289 B2UniversitäT ZüRich · 2016
- CMV vaccines11US 10,111,945 B2Hookipa Biotech GmbH · 2018
- Replication-defective arenavirus vectors11US 9,944,952 B2UniversitäT ZüRich · 2018
- Tri-segmented arenaviruses as vaccine vectors7US 10,722,564 B2Universite De Geneve · 2020